#1 Clinical Trials Search in Europe

Methylprednisolone Aceponate

Methylprednisolone Aceponate is a topical corticosteroid that has been the subject of several clinical trials for various skin conditions. These trials aim to evaluate its efficacy and safety in treating conditions such as atopic dermatitis, allergic contact eczema, and psoriasis. The studies explore different application methods, dosages, and compare it with other treatments to determine its potential benefits and possible side effects.

Table of Contents

What is Methylprednisolone Aceponate?

Methylprednisolone aceponate (MPA) is a topical medication that belongs to a class of drugs called glucocorticoids. It’s also known by brand names such as Advantan and Adventan[1]. This medication is primarily used to treat various skin conditions and is available as a cream, ointment, or emulsion[2].

Conditions Treated

Methylprednisolone aceponate is used to treat several skin conditions, including:

  • Atopic Dermatitis: Also known as eczema, this is a chronic skin condition characterized by itchy, inflamed skin[2].
  • Allergic Contact Eczema: A type of skin reaction that occurs when the skin comes into contact with an allergen[1].
  • Psoriasis: A condition that causes rapid buildup of skin cells, resulting in scaly, itchy, dry patches[5].

How It Works

Methylprednisolone aceponate works by reducing inflammation in the skin. It belongs to a group of medications called corticosteroids, which mimic the effects of hormones naturally produced by your adrenal glands. When applied to the skin, it helps to reduce redness, itching, and swelling associated with various skin conditions[4].

How It’s Administered

Methylprednisolone aceponate is typically applied directly to the affected areas of skin. The frequency of application can vary depending on the specific condition being treated and the severity of symptoms. Some common administration methods include:

  • Daily application for acute conditions[1].
  • Twice weekly application for maintenance therapy in conditions like atopic dermatitis[2].
  • Application of a thin layer to the affected area, usually measured in Finger Tip Units (FTU). One FTU is the amount of cream that fits on the tip of your finger from the first crease to the end[1].

Efficacy

Research has shown that methylprednisolone aceponate can be effective in treating various skin conditions:

  • In atopic dermatitis, it has been shown to reduce symptoms and prevent relapses when used as maintenance therapy[2].
  • For allergic contact eczema, it can provide itch relief and reduce inflammation[1].
  • In psoriasis, it has shown effectiveness in reducing symptoms when applied topically[5].

Potential Side Effects

While methylprednisolone aceponate is generally well-tolerated, like all medications, it can have side effects. Some potential side effects include:

  • Skin thinning (atrophy): This is monitored in long-term use through visual assessment and ultrasound measurements[2].
  • Changes in skin color
  • Burning or stinging sensation at the application site

It’s important to use this medication as directed by your healthcare provider and report any unusual side effects.

Ongoing Research

Researchers continue to study methylprednisolone aceponate to better understand its effects and potential uses:

  • A study is investigating its use in preventing transcutaneous sensitization in infants with atopic dermatitis[3].
  • Another study is examining how genes respond to glucocorticoids like methylprednisolone aceponate, which could lead to the development of more targeted treatments with fewer side effects[4].

These ongoing studies demonstrate the continued interest in improving our understanding and use of methylprednisolone aceponate in treating various skin conditions.

Aspect Details
Drug Name Methylprednisolone Aceponate
Conditions Studied Atopic Dermatitis, Allergic Contact Eczema, Psoriasis
Application Methods Topical cream or emulsion
Dosage Frequencies Ranging from twice daily to twice weekly
Age Groups Infants (2 months) to Adults (up to 64 years)
Primary Outcomes Measured Itch relief time, Changes in eczema severity (EASI), Skin thickness changes
Secondary Outcomes Quality of life improvements, Adverse events monitoring
Comparison Treatments Topical calcineurin inhibitors, Placebos
Study Designs Randomized controlled trials, Observational studies

FAQ

  • What is Methylprednisolone Aceponate used for in clinical trials? Methylprednisolone Aceponate is being studied in clinical trials for various skin conditions, including atopic dermatitis, allergic contact eczema, and psoriasis. It is used as a topical treatment to reduce inflammation and relieve symptoms associated with these conditions.
  • How is Methylprednisolone Aceponate applied in these trials? In the trials, Methylprednisolone Aceponate is typically applied as a cream or emulsion directly to the affected skin areas. The frequency of application varies depending on the study, ranging from twice daily to twice weekly, and for different durations based on the specific trial protocol.
  • What are some of the outcomes being measured in these trials? The trials measure various outcomes, including the time to itch relief, changes in eczema severity using scales like EASI (Eczema Area and Severity Index), changes in skin thickness, quality of life improvements, and the occurrence of any adverse events or side effects.
  • Are there any comparisons being made with other treatments? Yes, some trials compare Methylprednisolone Aceponate with other treatments or placebos. For example, one study compares it with topical calcineurin inhibitors in children with atopic dermatitis, while another compares it with a placebo in maintaining treatment for atopic dermatitis.
  • What age groups are involved in these clinical trials? The clinical trials involve various age groups, from infants as young as 2 months old to adults. Some studies specifically focus on children in their first year of life, while others include adult participants up to 64 years old.

Ongoing Clinical Trials on Methylprednisolone Aceponate

  • Study Comparing Methylprednisolone Aceponate Ointment and a Drug Combination for Patients with Mild to Moderate Atopic Dermatitis

    Recruiting

    1 1
    Investigated drugs:
    Germany

  • Study Comparing Methylprednisolone Aceponate Creams and a Non-Active Cream for Patients with Mild to Moderate Atopic Dermatitis

    Recruiting

    1 1 1
    Investigated drugs:
    Germany

  • Study on the Effect of a New Moisturiser with Paraffin and Liquid Paraffin on Preventing Eczema Relapse in Children

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Sweden

Glossary

  • Atopic Dermatitis: A chronic skin condition characterized by itchy, inflamed skin. It's a type of eczema that commonly begins in childhood.
  • Allergic Contact Eczema: A skin reaction that occurs when your skin comes into contact with a substance that triggers an allergic reaction.
  • Topical Calcineurin Inhibitors: A class of medications applied to the skin to treat certain skin conditions by suppressing the immune system's response in the affected area.
  • EASI (Eczema Area and Severity Index): A tool used to measure the extent and severity of atopic dermatitis, considering factors like the area affected and the intensity of symptoms.
  • Proactive Therapy: A treatment approach where medication is applied regularly to prevent flare-ups, even when symptoms are not present.
  • Emollients: Moisturizing treatments applied directly to the skin to soothe and hydrate it, often used in managing dry skin conditions.
  • Transcutaneous Sensitization: The process by which a person becomes sensitive to a substance through skin exposure, potentially leading to allergic reactions.
  • Glucocorticoids: A class of steroid hormones that reduce inflammation in the body, used in various medical treatments including skin conditions.
  • Immunosuppressive: A property of certain drugs that reduce the strength of the body's immune system, often used to treat autoimmune conditions.

References

  1. https://clinicaltrials.gov/study/NCT01529320
  2. https://clinicaltrials.gov/study/NCT00185510
  3. https://clinicaltrials.gov/study/NCT04900948
  4. https://clinicaltrials.gov/study/NCT02798523
  5. https://clinicaltrials.gov/study/NCT00236171